The intersection of COVID-19 and autoimmunity

• Published in: The Journal of clinical investigation Vol. 131; no. 24; pp. 1 - 9
• Main Authors: Knight, Jason S., Caricchio, Roberto, Casanova, Jean-Laurent, Combes, Alexis J., Diamond, Betty, Fox, Sharon E., Hanauer, David A., James, Judith A., Kanthi, Yogendra, Ladd, Virginia, Mehta, Puja, Ring, Aaron M., Sanz, Ignacio, Selmi, Carlo, Tracy, Russell P., Utz, Paul J., Wagner, Catriona A., Wang, Julia Y., McCune, William J.
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 15.12.2021
• Subjects: Age; Animals; Asymptomatic; Asymptomatic infection; Autoantibodies; Autoantibodies - chemistry; Autoimmune Diseases; Autoimmunity; Autoimmunity - immunology; B-Lymphocytes - cytology; Biomedical research; Complications; Coronaviruses; COVID-19; COVID-19 - immunology; COVID-19 - physiopathology; Cytokines; Cytokines - metabolism; Disease; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor - metabolism; Host-virus relationships; Humans; Infections; Inflammation; Influenza; Interferon; Interleukin-1 - metabolism; Interleukin-6 - metabolism; Kinases; Long COVID; Lymphocytes B; Macrophage Activation; Male; Medical research; Medicine, Experimental; Mice; Patients; Phospholipids - metabolism; Physiological aspects; Pneumonia; Respiratory failure; Review; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Signal Transduction; Thrombosis; Viral infections; United States
• ISSN: 1558-8238; 0021-9738; 1558-8238
• DOI: 10.1172/JCI154886

Acute COVID-19, caused by SARS-CoV-2, is characterized by diverse clinical presentations, ranging from asymptomatic infection to fatal respiratory failure, and often associated with varied longer-term sequelae. Over the past 18 months, it has become apparent that inappropriate immune responses contribute to the pathogenesis of severe COVID-19. Researchers working at the intersection of COVID-19 and autoimmunity recently gathered at an American Autoimmune Related Diseases Association Noel R. Rose Colloquium to address the current state of knowledge regarding two important questions: Does established autoimmunity predispose to severe COVID-19? And, at the same time, can SARS-CoV-2 infection trigger de novo autoimmunity? Indeed, work to date has demonstrated that 10% to 15% of patients with critical COVID-19 pneumonia exhibit autoantibodies against type I interferons, suggesting that preexisting autoimmunity underlies severe disease in some patients. Other studies have identified functional autoantibodies following infection with SARS-CoV-2, such as those that promote thrombosis or antagonize cytokine signaling. These autoantibodies may arise from a predominantly extrafollicular B cell response that is more prone to generating autoantibody-secreting B cells. This Review highlights the current understanding, evolving concepts, and unanswered questions provided by this unique opportunity to determine mechanisms by which a viral infection can be exacerbated by, and even trigger, autoimmunity. The potential role of autoimmunity in post-acute sequelae of COVID-19 is also discussed.